Generics BulletinAs Mallinckrodt and Endo continue to work towards merging their businesses, the firms have revealed further details of their plans for the combined company’s generics and sterile injectables unit, whi
In VivoBiopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
In VivoIn the top alliance by deal value, Zealand Pharma entered into a global collaboration and license agreement with Roche to develop petrelintide, Zealand’s amylin analog as a foundational therapy for we
ScripMerger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu